The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
This study has been completed.
University Hospital, Gentofte, Copenhagen
Novo Nordisk A/S
University of Copenhagen
Information provided by (Responsible Party):
Signe H Østoft, MD, University Hospital, Gentofte, Copenhagen
First received: May 24, 2012
Last updated: September 4, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||August 2013|
|Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Østoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsbøll T. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014 Jul;37(7):1797-805. doi: 10.2337/dc13-3007.